A Chinese survey of clinical practice on the management of thyroid eye disease
Authors' conclusion
The study documented the consistency and differences between current clinical practices in the management of TED in China and the recently updated guidelines. There was a remarkable difference between ophthalmology and endocrinology departments, warranting management optimization.
Study context
- Population
- Endocrinologists and ophthalmologists in China managing thyroid eye disease (TED); survey April–May 2023questionnaires collected
- Participants
- 289 participants
- Exposure
- Endocrinologists vs Ophthalmologists
- Endocrinologistsn = 165
- Ophthalmologistsn = 124
- Outcome
- Current clinical practice in TED management in China
Methodological detailsonline questionnaire survey
- Online questionnaire survey
Main finding
As reported in the abstract
- Participants reporting an multidisciplinary treatment (MDT) clinical pattern for TED in their institution
- 36.7%
- Coverage of biological agents
- around 10% or lower
- Participants believing TED incidence has increased in recent years
- 62.6%
- Mild active TED: endocrinologists inclined to recommend therapy for hyperthyroidism alone
- 39.4%
- Mild active TED: ophthalmologists preferred orbital corticosteroid injections
- 43.6%
- Moderate to severe active TED: high-dose IV corticosteroid most widely used
- 94.8%
- Most recognized second-line therapy: orbital radiotherapy combined with immunosuppressive agents
- 43.6%
Observational data: associations, not effects.
Original publication
A Chinese survey of clinical practice on the management of thyroid eye disease. Eur Thyroid J. Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →